Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

572 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Transmitted Drug Resistance to Integrase-Based First-Line Human Immunodeficiency Virus Antiretroviral Regimens in Mediterranean Europe.
de Salazar A, Viñuela L, Fuentes A, Teyssou E, Charpentier C, Lambert-Niclot S, Serrano-Conde E, Pingarilho M, Fabeni L, De Monte A, Stefic K, Perno CF, Aguilera A, Falces I, Delgado R, Fernandes S, Diogo I, Gomes P, Paraskevis D, Santoro MM, Ceccherini-Silberstein F, Marcelin AG, Garcia F. de Salazar A, et al. Among authors: charpentier c. Clin Infect Dis. 2023 May 3;76(9):1628-1635. doi: 10.1093/cid/ciac972. Clin Infect Dis. 2023. PMID: 36571282
Resistance profiles of emtricitabine and lamivudine in tenofovir-containing regimens.
Marcelin AG, Charpentier C, Wirden M, Landman R, Valantin MA, Simon A, Katlama C, Yeni P, Descamps D, Aubron-Olivier C, Calvez V. Marcelin AG, et al. Among authors: charpentier c. J Antimicrob Chemother. 2012 Jun;67(6):1475-8. doi: 10.1093/jac/dks047. Epub 2012 Feb 26. J Antimicrob Chemother. 2012. PMID: 22371439
Prevalence of pre-existing resistance-associated mutations to rilpivirine, emtricitabine and tenofovir in antiretroviral-naive patients infected with B and non-B subtype HIV-1 viruses.
Lambert-Niclot S, Charpentier C, Storto A, Fofana DB, Soulié C, Fourati S, Visseaux B, Wirden M, Morand-Joubert L, Masquelier B, Flandre P, Calvez V, Descamps D, Marcelin AG. Lambert-Niclot S, et al. Among authors: charpentier c. J Antimicrob Chemother. 2013 Jun;68(6):1237-42. doi: 10.1093/jac/dkt003. Epub 2013 Jan 29. J Antimicrob Chemother. 2013. PMID: 23361642
Rilpivirine, emtricitabine and tenofovir resistance in HIV-1-infected rilpivirine-naive patients failing antiretroviral therapy.
Lambert-Niclot S, Charpentier C, Storto A, Fofana D, Soulie C, Fourati S, Wirden M, Morand-Joubert L, Masquelier B, Flandre P, Calvez V, Descamps D, Marcelin AG. Lambert-Niclot S, et al. Among authors: charpentier c. J Antimicrob Chemother. 2014 Apr;69(4):1086-9. doi: 10.1093/jac/dkt463. Epub 2013 Dec 2. J Antimicrob Chemother. 2014. PMID: 24302653
Antiretroviral-naive and -treated HIV-1 patients can harbour more resistant viruses in CSF than in plasma.
Soulie C, Descamps D, Grudé M, Schneider V, Trabaud MA, Morand-Joubert L, Delaugerre C, Montes B, Barin F, Ferre V, Raymond S, Jeulin H, Alloui C, Yerly S, Pallier C, Reigadas S, Signori-Schmuck A, Guigon A, Fafi-Kremer S, Haïm-Boukobza S, Mirand A, Maillard A, Vallet S, Roussel C, Assoumou L, Calvez V, Flandre P, Marcelin AG; ANRS Resistance AC11 Group. Soulie C, et al. J Antimicrob Chemother. 2015 Feb;70(2):566-72. doi: 10.1093/jac/dku419. Epub 2014 Oct 25. J Antimicrob Chemother. 2015. PMID: 25344810
Cross-resistance to elvitegravir and dolutegravir in 502 patients failing on raltegravir: a French national study of raltegravir-experienced HIV-1-infected patients.
Fourati S, Charpentier C, Amiel C, Morand-Joubert L, Reigadas S, Trabaud MA, Delaugerre C, Nicot F, Rodallec A, Maillard A, Mirand A, Jeulin H, Montès B, Barin F, Bettinger D, Le Guillou-Guillemette H, Vallet S, Signori-Schmuck A, Descamps D, Calvez V, Flandre P, Marcelin AG; ANRS AC11 Resistance Study Group. Fourati S, et al. Among authors: charpentier c. J Antimicrob Chemother. 2015 May;70(5):1507-12. doi: 10.1093/jac/dku535. Epub 2015 Jan 3. J Antimicrob Chemother. 2015. PMID: 25558077 Free article.
HIV-1 subtype B-infected MSM may have driven the spread of transmitted resistant strains in France in 2007-12: impact on susceptibility to first-line strategies.
Frange P, Assoumou L, Descamps D, Chéret A, Goujard C, Tran L, Gousset M, Avettand-Fenoël V, Bocket L, Fafi-Kremer S, Guinard J, Morand-Joubert L, Nicot F, Plantier JC, Rogez S, Wirden M, Rouzioux C, Meyer L, Chaix ML; French ANRS CO 6 PRIMO Cohort, the ANRS 147 OPTIPRIM Clinical Trial and the AC11 Resistance Study Groups; French ANRS CO 6 PRIMO Cohort the ANRS 147 OPTIPRIM Clinical Trial and the AC11 Resistance Study Groups. Frange P, et al. J Antimicrob Chemother. 2015 Jul;70(7):2084-9. doi: 10.1093/jac/dkv049. Epub 2015 Feb 26. J Antimicrob Chemother. 2015. PMID: 25885327
Disparities in HIV-1 transmitted drug resistance detected by ultradeep sequencing between men who have sex with men and heterosexual populations.
Todesco E, Charpentier C, Bertine M, Wirden M, Storto A, Desire N, Grude M, Nguyen T, Sayon S, Yazdanpanah Y, Katlama C, Descamps D, Calvez V, Marcelin AG. Todesco E, et al. Among authors: charpentier c. HIV Med. 2017 Oct;18(9):696-700. doi: 10.1111/hiv.12508. Epub 2017 Apr 26. HIV Med. 2017. PMID: 28444829 Free article.
572 results